Shimomura, Akihiko http://orcid.org/0000-0002-2557-8170
Yoshida, Masayuki
Kubo, Takashi
Yamashita, Satoshi
Noguchi, Emi
Nagayama, Aiko
Hanamura, Toru
Okazaki, Miki
Mukohara, Toru
Tsuruga, Asako
Tanaka, Kiyo
Kawamura, Yukino
Higuchi, Toru
Takahashi, Yoko
Kurozumi, Sasagu
Hayashida, Tetsu
Ichikawa, Hitoshi
Ushijima, Toshikazu
Suto, Akihiko
Funding for this research was provided by:
Chugai Pharmaceutical Co. Ltd.
Article History
Received: 12 May 2022
Accepted: 29 November 2022
First Online: 9 December 2022
Declarations
:
: Dr. Shimomura reports grants from Chugai Pharmaceutical during the conduct of the study, in addition to grants and personal fees from Chugai Pharmaceutical, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi Sankyo, grants, and personal fees from Eisai, grants from Taiho Pharmaceutical, grants from Mochida Pharmaceutical, personal fees from Pfizer, personal fees from Novartis, personal fees from Eli-Lilly, personal fees from Kyowa Kirin, personal fees from Takeda Pharmaceutical, and personal fees from MSD outside the submitted work. Dr. Kubo reports personal fees from Sysmex, outside the submitted work. Dr. Noguchi reports personal fees from Pfizer, personal fees from Taiho Pharmaceutical, personal fees from Eli Lilly, personal fees from AstraZeneca, personal fees from Chugai Pharmaceutical, personal fees from Eisai, and personal fees from Novartis outside the submitted work. Dr. Nagayama reports personal fees from Chugai Pharmaceutical, personal fees from Pfizer, personal fees from AstraZeneca, and personal fees from Kyowa Kirin outside the submitted work. Dr. Mukohara reports grants and other contributions from Daiichi-Sankyo, grants from Sysmex, grants and other contribution from Eisai, grants from MSD, grants and other contributions from Pfizer, grants and other contributions from Novartis, grants from Sanofi, grants and other contributions from Chugai Pharmaceutical, other contributions from Eli-Lilly, grants and other contributions from Astra Zeneca, other contributions from Kyowa-Kirin, other contributions from Taiho Pharmaceutical, and grants from Ono Pharmaceutical outside the submitted work. Dr. Kurozumi reports personal fees from Chugai Pharmaceutical, personal fees from Daiichi Sankyo, personal fees from Taiho Pharmaceutical, personal fees from Eli-Lilly, personal fees from MSD, personal fees from AstraZeneca, personal fees from Pfizer, personal fees from Takeda Pharmaceutical, and personal fees from Novartis outside the submitted work. Dr. Hayashida reports grants and personal fees from Chugai Pharmaceutical, personal fees from Pfizer, personal fees from AstraZeneca, grants and personal fees from Kyowa Kirin, grants and personal fees from Eisai, grants from Taiho Pharmaceutical, grants and personal fees from Eli-Lilly, grants from Roche Diagnostic, and grants from Shionogi Seiyaku outside the submitted work. Dr. Ichikawa reports grants from Chugai Pharmaceutical, Eisai, Healios, and Ono Pharmaceutical outside the submitted work. The other authors declare no potential conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the National Center for Global Health and Medicine, Tokyo (Date: March 20, 2020; No. NCGM-G-003481-01).
: The requirement for informed consent to participate was waived because of the retrospective nature of the study.
: Not applicable.